Related Experiment Videos
Bisphosphonates in cancer therapy
1Novartis Pharma AG, Basel, Switzerland. jonathan.green@pharma.novartis.com
Abstract:
Bisphosphonates inhibit osteoclast-mediated bone resorption in metastatic bone disease. A wealth of preclinical data have begun to shed light on the complex mechanisms by which bisphosphonates inhibit bone resorption and interfere with the formation and growth of bone metastases. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway, which results in the inhibition of osteoclast function and the induction of apoptosis in osteoclasts and tumor cells alike. There is now extensive evidence that bisphosphonates have cytostatic activity against tumor cell lines and inhibit tumor cell adhesion and invasion of the extracellular matrix. These data are supported by a growing body of evidence from animal models demonstrating that bisphosphonates can reduce skeletal tumor burden. However, it remains unclear whether this reduction reflects a direct antitumor effect or an indirect effect via osteoclast inhibition and alteration of the bone microenvironment. Further preclinical studies are needed to elucidate these biochemical mechanisms fully; ultimately, well-controlled clinical trials will be required to investigate whether the antitumor potential of bisphosphonates translates into a significant clinical benefit for patients with cancer.
Insights
Bisphosphonates combat bone metastases by inhibiting osteoclast activity and potentially acting directly on tumor cells. Further research is needed to confirm their antitumor effects and clinical benefits in cancer patients.
Area of Science:
- Oncology
- Pharmacology
- Bone Biology
Background:
- Bisphosphonates are established treatments for metastatic bone disease, primarily by inhibiting osteoclast-mediated bone resorption.
- Preclinical data suggest complex mechanisms involving bisphosphonates' effects on bone metastases.
- Nitrogen-containing bisphosphonates target the mevalonate pathway, impacting osteoclast function and inducing apoptosis in osteoclasts and tumor cells.
Purpose of the Study:
- To explore the multifaceted mechanisms by which bisphosphonates inhibit bone resorption and interfere with bone metastasis.
- To investigate the direct antitumor effects of bisphosphonates, including cytostatic activity, inhibition of cell adhesion, and invasion.
- To evaluate the potential clinical benefit of bisphosphonates in cancer patients with bone metastases.
Main Methods:
- Review of preclinical data on bisphosphonate mechanisms.
- Analysis of studies on the mevalonate pathway inhibition by nitrogen-containing bisphosphonates.
- Examination of evidence from animal models regarding skeletal tumor burden reduction.
Main Results:
- Bisphosphonates inhibit osteoclast function and induce apoptosis in osteoclasts and tumor cells.
- Evidence shows bisphosphonates possess cytostatic activity and inhibit tumor cell adhesion and invasion.
- Animal models indicate bisphosphonates can reduce skeletal tumor burden.
Conclusions:
- The precise mechanisms by which bisphosphonates affect bone metastases require further elucidation.
- It is unclear if observed reductions in tumor burden are due to direct antitumor effects or indirect osteoclast inhibition.
- Clinical trials are necessary to determine the therapeutic potential of bisphosphonates against cancer bone metastases.